{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"43.9","upperLimit":"85.7","value":"70"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Time elapsed between Day 0 and death from any cause, whichever came first, assessed up to 2 years.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients treated on Dose Level 1 through Dose Level 6. All patients received Melphalan 200 mg/m\\^2 total (140 mg/m\\^2 total for patients with Creatinine Clearance \\<70 ml/min).\n\nDose Level 1; Bendamustine 30 mg/m\\^2 total Dose Level 2; Bendamustine 60 mg/m\\^2 total Dose Level 3; Bendamustine 90 mg/m\\^2 total Dose Level 4; Bendamustine 120 mg/m\\^2 total Dose Level 5; Bendamustine 150 mg/m\\^2 total Dose Level 6; Bendamustine 225 mg/m\\^2 total","id":"OG000","title":"Phase 1"}],"paramType":"MEDIAN","populationDescription":"Phase 1 includes all patients treated on Phase 1 of the study (Dose Levels 1-6). All cohorts were evaluated as one group for assessment of overall survival, as overall survival is a secondary endpoint and there was no intent to stratify by cohort for the analysis. The number of patients per cohort is also too small for to evaluate by cohort.","reportingStatus":"POSTED","timeFrame":"From Day 0 until time of death, assessed up to 2 years.","title":"Overall Survival at 2 Years (Phase 1)","type":"SECONDARY","unitOfMeasure":"Percentage of participants alive"}